sr141716 has been researched along with Non-alcoholic Fatty Liver Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jorgačević, B; Mladenović, D; Radosavljević, T; Šobajić, S; Vesković, M; Vučević, D; Vukićević, RJ; Đuričić, I | 1 |
| El-Kerdasy, HI; Hussien, NI; Ibrahim, ME | 1 |
| Jorgačević, B; Mladenović, D; Radosavljević, T; Todorović, V; Vesković, M; Vučević, D; Vukićević, D; Vukićević, RJ | 1 |
| Bao, Z; Hu, X; Jia, M; Shi, D; Yao, J; Yu, X; Zhan, X; Zhang, Y | 1 |
| Dragutinović, V; Ješić Vukićević, R; Jorgačević, B; Mladenović, D; Ninković, M; Radosavljević, T; Vatazević, A; Vesković, M; Vučević, D | 1 |
| Ganesh, S; Rustgi, VK | 1 |
| Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Elshewehy, AM; Kilpatrick, ES; Sathyapalan, T | 1 |
| Botha, AJ; Crook, MA; Dar, A; McMahon, Z; Oben, J; Pendleton, S; Wierzbicki, AS | 1 |
1 review(s) available for sr141716 and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anticholesteremic Agents; Antioxidants; Cannabinoid Receptor Antagonists; Cholagogues and Choleretics; Fatty Acids, Omega-3; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Pentoxifylline; Piperidines; Probiotics; Pyrazoles; Rimonabant; Synbiotics; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2016 |
1 trial(s) available for sr141716 and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
Topics: Body Mass Index; Cannabinoid Receptor Antagonists; Cytokines; Female; Hepatocyte Growth Factor; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant | 2016 |
6 other study(ies) available for sr141716 and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Diet, High-Fat; Fatty Acids, Nonesterified; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB2; Rimonabant | 2017 |
Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin.
Topics: Activins; Animals; Biomarkers; Cannabinoid Receptor Antagonists; Cytoprotection; Disease Models, Animal; Follistatin; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Transforming Growth Factor beta | 2017 |
The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease.
Topics: Adipokines; Adipose Tissue; Animals; Blood Glucose; Cannabinoid Receptor Antagonists; Cytokines; Diet, High-Fat; Disease Models, Animal; Drug Evaluation, Preclinical; Glucose; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Receptor, Cannabinoid, CB1; Rimonabant | 2019 |
Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.
Topics: Cannabinoid Receptor Antagonists; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Lipogenesis; Non-alcoholic Fatty Liver Disease; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2014 |
Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease.
Topics: Animals; Cannabinoid Receptor Antagonists; Diet, High-Fat; Disease Models, Animal; Glutathione; Liver; Male; Malondialdehyde; Metals; Mice; Mice, Inbred C57BL; Nitrates; Nitrites; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Piperidines; Pyrazoles; Rimonabant; Superoxide Dismutase | 2015 |
Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study.
Topics: Adult; Biomarkers; Cannabinoid Receptor Modulators; Cholesterol; Fatty Liver; Female; Humans; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity, Morbid; Piperidines; Pyrazoles; Retrospective Studies; Rimonabant; Safety-Based Drug Withdrawals; Triglycerides; Weight Loss | 2011 |